Novo Nordisk faces more gloom from price cuts in crowded anti-obesity drugs market
Danish group’s challenges mount despite winning reprieve after Hims & Hers withdraws plan to sell copycat Wegovy pill
Danish group’s challenges mount despite winning reprieve after Hims & Hers withdraws plan to sell copycat Wegovy pill
US telehealth group will sell product for $49 a month, a third that of its Danish competitor
Novo Nordisk had accused the telehealth company of breaching its patent on Wegovy
Shares in US company fall 16% after FDA announces investigation into unregulated medication
Danish drugmaker expects sales and profit growth at lower end of its guidance this year
Novo Nordisk’s Wegovy tablet offers Danish drugmaker window to win back market share from Eli Lilly
Share slide wipes more than €60bn off value of Danish maker of Ozempic and Wegovy
